Log in
NYSE:ANIX

ITUS Stock Forecast, Price & News

$2.49
+0.19 (+8.26 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.29
Now: $2.49
$2.54
50-Day Range
$1.79
MA: $2.31
$2.96
52-Week Range
$1.33
Now: $2.49
$4.24
Volume173,804 shs
Average Volume245,647 shs
Market Capitalization$59.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anixa Biosciences, Inc. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Computer Peripherals
Sub-IndustryN/A
CUSIPN/A
CIKN/A
WebN/A
Phone(408) 708-9808

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$59.23 million
Next Earnings Date1/14/2021 (Estimated)
OptionableNot Optionable
$2.49
+0.19 (+8.26 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ITUS (NYSE:ANIX) Frequently Asked Questions

How has ITUS's stock been impacted by Coronavirus?

ITUS's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANIX shares have increased by 20.3% and is now trading at $2.49.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ITUS?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ITUS in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ITUS
.

When is ITUS's next earnings date?

ITUS is scheduled to release its next quarterly earnings announcement on Thursday, January 14th 2021.
View our earnings forecast for ITUS
.

How were ITUS's earnings last quarter?

ITUS Corporation (NYSE:ANIX) issued its quarterly earnings data on Monday, March, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13).
View ITUS's earnings history
.

What price target have analysts set for ANIX?

2 brokers have issued 12 month price objectives for ITUS's stock. Their forecasts range from $8.00 to $8.50. On average, they anticipate ITUS's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 231.3% from the stock's current price.
View analysts' price targets for ITUS
.

Who are some of ITUS's key competitors?

What other stocks do shareholders of ITUS own?

Who are ITUS's key executives?

ITUS's management team includes the following people:
  • Amit Kumar, Executive Chairman, President & CEO
  • Michael J. Catelani, Chief Operating & Financial Officer
  • John A. Roop, Senior Vice President-Engineering
  • Anthony Campisi, Vice President-Engineering

What is ITUS's stock symbol?

ITUS trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANIX."

How do I buy shares of ITUS?

Shares of ANIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ITUS's stock price today?

One share of ANIX stock can currently be purchased for approximately $2.49.

How big of a company is ITUS?

ITUS has a market capitalization of $59.23 million.

How can I contact ITUS?

The company can be reached via phone at (408) 708-9808.

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.